Podcast + Q&A: Device-Makers Shouldn't Ignore Pharma Quality Metrics Initiative, Attorney Says
This article was originally published in The Gray Sheet
In a Dec. 9 podcast interview at the Food and Drug Law Institute Enforcement, Litigation and Compliance meeting in Washington, D.C., Alston & Bird partner Cathy Burgess discussed how the FDA’s quality metrics initiative for pharmaceutical companies may also impact expectations for device manufacturers down the line.
You may also be interested in...
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.